Raymond L. Comenzo, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Raymond L. Comenzo, MD

Raymond L. Comenzo, MD

Healthcare Professional
Director
John C. Davis Myeloma and Amyloid Program
Tufts Medical Center
800 Washington Street
Boston, Massachusetts, United States
Dr. Raymond Comenzo received his medical degree from Boston University School of Medicine. He completed his internship and residency in medicine at Boston City Hospital, followed by his fellowship in hematology/oncology at New England Medical Center. Dr. Comenzo is professor of medicine and pathology at Tufts University School of Medicine and director of the Blood Bank and Stem Cell Processing Laboratory.
 
Dr. Comenzo is board certified in internal medicine, medical oncology, and hematology. He is on the Scientific Advisory Board, International Myeloma Foundation; Board of Directors, Amyloidosis Foundation, and the Eastern Clinical Oncology Group (ECOG), Myeloma Committee. In addition he holds memberships in the Massachusetts Medical Society, American Society of Hematology (ASH), and the American Association of Blood Banks. 
 
Dr. Comenzo’s research mainly focuses on autologous stem cell transplantation for systemic AL-amyloidosis, association of immunoglobulin light chain variable region germline gene use and organ tropism in AL-amyloidosis, defining the “fitness costs” to clonal plasma cells exacted by producing AL light chains and on the impact of proteasome inhibitors on such cells, novel model of plasma cell apoptosis triggered by knockdown of Ig light chain expression, pre-clinical evaluations of monoclonal antibodies elotuzumab (Bristol) and daratumumab (Janssen) with NK cells from SCT patients as effectors and lipidoid nanoparticle delivery systems targeting human plasma cells.
 
 
Representative Publications:
 
 
 
 
 
 
view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close